期刊文献+

齐拉西酮与利培酮对精神分裂症患者的疗效及其对血糖血脂的影响 被引量:5

Comparative study of curative effect and blood glucose and lipid in schizophrenic patients who treated with ziprasidone and risperidone
下载PDF
导出
摘要 目的观察齐拉西酮与利培酮对精神分裂症患者的治疗效果及其对血糖、血脂的影响。方法将96例精神分裂症患者随机分为采用齐拉西酮治疗的齐拉西酮组与采用利培酮治疗的利培酮组,共治疗8周,于基线水平(治疗前)、治疗第4周末和第8周末分别对患者的血糖、血脂进行测定。结果两组治疗前阳性和阴性症状量表(PANSS)阳性症状评分、阴性症状评分比较,差异无统计学意义(P>0.05)。两组治疗第4、8周评分与基线评分比较均显著下降,差异均有统计学意义(P<0.05),而两组间比较差异无统计学意义(P>0.05)。治疗8周后,齐拉西酮组有效率为91.7%,利培酮组有效率为89.6%,两组间比较差异无统计学意义(P>0.05)。齐拉西酮组治疗后血脂、血糖水平与基线水平比较差异无统计学意义(P>0.05)。利培酮组治疗后血脂、血糖水平增加明显,与基线水平比较差异有统计学意义(P<0.05)。结论齐拉西酮与利培酮治疗精神分裂症疗效相当。齐拉西酮对精神分裂症患者的血糖、血脂无明显影响,而利培酮可升高血糖、血脂,长期服用需注意其副作用。 Objective To observe the effects of ziprasidone and risperidone on patients with schizophrenia and their influence on bloodglucoseandlipids.Methods 96patientswithschizophrenicenrolledinthestudywererandomlydividedintotwogroups,zi‐prasidone and risperidone group ,and both were treated for 8 weeks .Their blood glucose ,blood lipid of base line and at the end of the 4th ,8th week were determined respectively .Results The positive and negative symptoms scores of the two groups by using Positive and Negative Syndrome Scale(PANSS) before and after treatment were not statistically different(P〉 0 .05) .Compared with the baseline scores ,scores at the end of 4th and 8th week in both ziprasidone and risperidone groups significantly decreased(P〈0 .05) ,but there was no statistically significant difference between the two groups(P〉0 .05) .After 8 weeks′ treatment ,the ef‐fective rate was 91 .7% in ziprasidone groups and 89 .6% in risperidone group .There were no significant differences between the two groups(P〉0 .05) .The blood lipids and glucose levels were less increased after ziprasidone treatment ,but was not statistically significant(P〉0 .05) .The blood lipids and glucose levels significantly increased after risperidone treatment(P〈0 .05) .Conclusion Ziprasidone and risperidone had the same effect on schizophrenia .Ziprasidone had no effect on blood glucose and lipids in schizo‐phrenic patients ,while risperidone could increase blood glucose and lipids level ,we should pay attention to the side effects of long‐term use .
出处 《国际检验医学杂志》 CAS 2015年第17期2471-2472,2475,共3页 International Journal of Laboratory Medicine
基金 佛山市医学类科技攻关项目(2014AB001693)
关键词 齐拉西酮 利培酮 血糖 血脂 精神分裂症 ziprasidone risperidone blood glucose blood lipids schizophrenia
  • 相关文献

参考文献9

  • 1Knegtering R,Baselmans P, Castelein S, et al. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolac- tin levels[J]. Am J Psychiatry, 2005,162(5) : 1010-1012.
  • 2Tschoner A, Engl J, Rettenbacher M, et al. Effects of six second Generation antipsychotics on body weight and metabolism-risk assessment and results from a prospective study [J]. Pharmacopsychiatry, 2009,42 (1) : 29-34.
  • 3崔开艳,刘兰芬,杨丽敏.齐拉西酮与利培酮对精神分裂症患者泌乳素及体质量、血糖、血脂的影响[J].精神医学杂志,2010,23(1):7-9. 被引量:55
  • 4Findling RL, Cavus I, Pappadopulos E, et al. Ziprasidone in adoles- cents with schizophrenia:results from a placebo-controlled effica- cy and tong-term open-extension study[J]. J Child Adolese psy- ehopharmaeol, 2013,23(8) :531-544.
  • 5Taylor DM,Mcaskill R. Atypical antipsychotics and weight gain-a systematic review[J]. Acta Psychiatr Scand, 2000, 101 (6) : 416-432.
  • 6Ryan MC, Thakore JH. Physical Consequences of schizophrenia and its treatment : the metabolic syndrome [J ]. Life Sci, 2002,71 (3) :239-257.
  • 7Weiden PJ, Mackell JA, Mcdonnell DD. Obesity as a risk factor for antipsychotic noncompliance[J]. Schizophr Res, 2004,66 ( 1 ) : 51- 57.
  • 8Wirshing DA,Spellberg BJ,Erhart SM,et al. Novel antipsychotics and new onset diabetes[J]. Biol Psychiatry, 1998,44(8) :778-783.
  • 9汪春运.齐哌西酮的精神科应用[J].国外医学(精神病学分册),2005,32(1):40-43. 被引量:90

二级参考文献32

  • 1刘洪光.氯丙嗪、氯氮平、利培酮对血糖和血脂的影响[J].临床心身疾病杂志,2004,10(2):77-78. 被引量:9
  • 2秦峰,余金龙,郑洪波,马崔,胡文生,蔡颖莲,陈宇薇.首发精神分裂症早期糖代谢变化研究[J].南方医科大学学报,2007,27(6):841-842. 被引量:12
  • 3Nasrallah HA, Newconer JW. Atypical antipsychotics and metabolic dysregulaiion: evahlating the risk/benefit equation and improxing the standardofeare[ J ]. ClinPsychopharmacol, 2004 , 24(5 Suppl 1) :S7 - 14.
  • 4Vohora D. Atypical antipsychotie drugs : emTent issues of safety and efficacy in the management of schizophrenia[ J]. Curr Opin Investig Drugs, 2007 , 8 (7) :531 - 538.
  • 5Tschoner A. Metabolic side effects of antipsychotic medication [J]. IntJClinPract, 2007, 61(8):1356-1370.
  • 6Montejo AL. Prolactin awareness: an essential consideration for physical health in schizophrenia [ J ]. Eur Neuropsychopharmacol, 2008 ,18 Suppl 2:S108 - 14.
  • 7Kleinberg DL, Davis JM, de Coster R, et al. Prolactin levels and adverse events in patients treated with risperidone [ J]. Clin Psychopharmacol, 1999,19 : 57 - 61.
  • 8Peuskens J. A Literature review of prolactin in schizophrenia [ D]. AstraZeniea, 1998,7.
  • 9Goodnick PJ, Rodriguez L, Santana O. Antipsychotics : impact on prolactin levels [ J ]. Expert Opin Pharmacother, 2002 , 3 (10) :1351 -91.
  • 10Bakos CD, Berecz R, Degrell I. Effect of atypical antipsychotics on metabolism [ J ]. Neuropsychopharmacol Hung,2004, 6 (2) : 86 - 89.

共引文献141

同被引文献46

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部